Sign In
Free Newsletter
Emergent BioSolutions signs 2nd COVID-19 vaccine deal
A Gaithersburg drug company has signed another deal to develop and manufacture another drug company's vaccine candidate for COVID-19.
Novavax gets $4M for COVID-19 vaccine, teams with Emergent
A Gaithersburg drug company has received $4 million in funding from a nongovernmental organization to develop a COVID-19 vaccine and is teaming with another Gaithersburg drug company for development and manufacturing.
Emergent closer to marketing cholera vaccine in Europe
Emergent BioSolutions Inc., a Gaithersburg life sciences firm that makes products to address public health threats received a favorable opinion from a European regulator for its cholera vaccine.
Emergent BioSolutions can pursue chikungunya vaccine in Europe
Emergent BioSolutions Inc., a Gaithersburg life sciences firm that makes products to address public health threats, has an agreement with the European Medicines Agency to pursue its proposed development plan for a vaccine candidate.
Emergent BioSolutions gets PRIME designation in Europe
Emergent BioSolutions Inc., a Gaithersburg life sciences firm that makes products to address public health threats, has been granted an important designation in Europe that could speed development of a vaccine candidate.
Emergent gets NIH contract for opioid addiction treatment
A Gaithersburg maker of products that address public health threats has received a new federal contract worth about $6.3 million for a treatment for opioid addiction.
Emergent Biosolutions has deal to buy Narcan maker for up to $735M
A Maryland life sciences company with a focus on public health threats has plans to buy the maker of a nasal spray used to treat people suspected of overdosing on opioids.
Emergent BioSolutions to pay $270M for vaccine maker
Emergent BioSolutions, a Gaithersburg-based pharmaceutical company that provides infectious disease vaccines for the U.S. government, is about to add cholera and typhoid vaccines to its arsenal. The company announced Thursday […]
Emergent BioSolutions gets $26M contract for medical treatment
The Centers for Disease Control and Prevention has awarded Emergent BioSolutions Inc. a $26 million contract to continue to supply a medical treatment to the government.
Emergent BioSolutions grows profit, revenue in 2017
Emergent BioSolutions Inc., a biotechnology company in Gaithersburg, had increased revenues and profits in unaudited financial results for its fourth quarter and the year 2017.
Md. firm gets $25M contract for nerve agent countermeasure
The U.S. State Department gave a one-year contract worth up to $25 million to Emergent BioSolutions Inc. of Gaithersburg to supply a drug and auto-injector that can be used to counter nerve agent […]
Emergent BioSolutions can borrow up to $300M in new credit facility
Emergent BioSolutions Inc., a life sciences company in Gaithersburg, now has more borrowing power, which it says it can use for strategic acquisitions. The company completed a new five-year, $200 […]
